Intellia Lonvo-z CRISPR — 2nd Drug·First In Vivo Edit. Swelling Attacks -87%
CRISPR-Cas9 won 2020 Nobel Chemistry. But first FDA approval (Casgevy 2023) was ex vivo edit. Intellia 2026.4.27 Phase 3 results — Lonvo-z = first in vivo edit clinical success. Swelling attacks -87%.
Key Announcement
Intellia Lonvo-z Phase 3: Lonvoguran ziclumeran, HAE (Hereditary Angioedema) target, 80 patients, swelling attacks -87% vs placebo, complete blockade 60%+ (placebo 11%), announcement 2026.4.27
Position: Casgevy 2023 = first CRISPR drug (ex vivo), Lonvo-z = 2nd CRISPR drug·first in vivo edit
CRISPR-Cas9
CRISPR: Bacterial immune origin, 2020 Nobel (Charpentier·Doudna), precision DNA editing
Cas9: DNA-cutting nuclease, gRNA targets, precision cut·edit
Ex Vivo vs In Vivo
Ex Vivo (Casgevy): Cell extraction (blood·marrow), lab CRISPR edit, patient re-injection, complex·high-cost·marrow transplant-like
In Vivo (Lonvo-z): Direct patient injection, liver·intracellular CRISPR edit, simple·outpatient, first clinical success
HAE (Hereditary Angioedema)
HAE: C1 esterase inhibitor deficiency·defect, hereditary·de novo mutation, facial·throat·abdominal swelling attacks, airway closure = emergency, lifelong treatment
Women: ~50/50 men:women, but hormonal impact (estrogen → attacks ↑), pregnancy·contraceptive impact, perimenopausal fluctuation
Lonvo-z Mechanism
Target: KLKB1 gene (Kallikrein B1), liver cell direct CRISPR edit, Kallikrein protein ↓, Bradykinin ↓ → swelling ↓
Clinical: 1-time injection expected lifetime effect, 87% attack reduction, 60%+ complete blockade, daily drug ↓ or eliminated
L73 Next Step Dimension - 2nd Axis
40 pillars + L67 PROTAC + L73 CRISPR in vivo = molecular receptor → protein degradation → DNA editing evolution.
Global CRISPR Trials
Active CRISPR trials: Casgevy (Vertex) first (ex vivo, 2023), Lonvo-z (Intellia) 2nd (in vivo, 2026), Exa-cel (Vertex) beta thalassemia·sickle cell, Beam Therapeutics base editing, Caribou cancer CRISPR
Future - Women’s Health
Current trials: Blood diseases·HAE
Future potential: BRCA1/2 variants (breast·ovarian cancer), APOE4 (Alzheimer·L68), MTHFR (nutrition·pregnancy), autoimmune (T-cell edit), collagen variants (Ehlers-Danlos)
Clinical entry: 2030~ expected
Safety·Ethics
Safety: Off-target editing, immune reactions, long-term effect verification needed, pregnancy·fetus absolute contraindicated
Ethics: Germline editing (offspring transmission) - prohibited, designer babies, access gap (cost $2~3M), global guidelines
Korean Implications
Korean CRISPR status: Casgevy MFDS review (2025~), some clinical trials, ethics·legal guidelines, cost burden
Lonvo-z adoption: FDA approval → Korean MFDS 2~3 yr, 2028~2030 expected, price $2M+ expected, insurance negotiation needed
FAQ
Q. 1-time injection lifelong effect? A. Phase 3 data 12+ months. Lifelong effect under verification. Some may need re-injection.
Q. CRISPR safe? A. Off-target verification, immune monitoring, pregnancy·germline absolute contraindicated. Doctor decision.
Q. Korean CRISPR availability? A. Casgevy MFDS review. Lonvo-z 2028~2030 expected. Cost burden.
Q. Women’s BRCA CRISPR? A. Future possible. Clinical entry 2030~. Currently BRCA = test·prevention·drugs.
Q. Offspring transmission? A. Somatic edit (in vivo CRISPR) no offspring impact. Germline edit = prohibited.
Conclusion
Intellia Lonvo-z = first in vivo CRISPR drug clinical success. HAE attacks -87%. L73 = 50 pillars + next step dimension (CRISPR in vivo 2nd axis). Molecular receptor → protein degradation → DNA editing evolution. Korea 2028~2030. Future women BRCA·APOE4·autoimmune potential.